BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 21973023)

  • 1. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells.
    Rettinger E; Kuçi S; Naumann I; Becker P; Kreyenberg H; Anzaghe M; Willasch A; Koehl U; Bug G; Ruthardt M; Klingebiel T; Fulda S; Bader P
    Cytotherapy; 2012 Jan; 14(1):91-103. PubMed ID: 21973023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic potential of IL-15-activated cytokine-induced killer cells against human neuroblastoma cells.
    Cappel C; Huenecke S; Suemmerer A; Erben S; Rettinger E; Pfirrmann V; Heinze A; Zimmermann O; Klingebiel T; Ullrich E; Bader P; Bremm M
    Pediatr Blood Cancer; 2016 Dec; 63(12):2230-2239. PubMed ID: 27433920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implication of different effector mechanisms by cord blood-derived and peripheral blood-derived cytokine-induced killer cells to kill precursor B acute lymphoblastic leukemia cell lines.
    Durrieu L; Lemieux W; Dieng MM; Fontaine F; Duval M; Le Deist F; Haddad E
    Cytotherapy; 2014 Jun; 16(6):845-56. PubMed ID: 24529554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
    Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
    Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.
    Pfirrmann V; Oelsner S; Rettinger E; Huenecke S; Bonig H; Merker M; Wels WS; Cinatl J; Schubert R; Klingebiel T; Bader P
    Cytotherapy; 2015 Aug; 17(8):1139-51. PubMed ID: 26072027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia.
    Linn YC; Hui KM
    Leuk Lymphoma; 2003 Sep; 44(9):1457-62. PubMed ID: 14565644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells.
    Hongeng S; Petvises S; Worapongpaiboon S; Rerkamnuaychoke B; Pakakasama S; Jootar S
    Int J Hematol; 2003 Feb; 77(2):175-9. PubMed ID: 12627854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.
    Pievani A; Borleri G; Pende D; Moretta L; Rambaldi A; Golay J; Introna M
    Blood; 2011 Sep; 118(12):3301-10. PubMed ID: 21821703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity.
    Satwani P; Bavishi S; Saha A; Zhao F; Ayello J; van de Ven C; Chu Y; Cairo MS
    Cytotherapy; 2014 Oct; 16(10):1431-40. PubMed ID: 24856896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
    Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
    Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-15 enhances cytokine induced killer (CIK) cytotoxic potential against epithelial cancer cell lines via an innate pathway.
    Iudicone P; Fioravanti D; Cicchetti E; Zizzari IG; Pandolfi A; Scocchera R; Fazzina R; Pierelli L
    Hum Immunol; 2016 Dec; 77(12):1239-1247. PubMed ID: 27615504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.
    Siegler U; Meyer-Monard S; Jörger S; Stern M; Tichelli A; Gratwohl A; Wodnar-Filipowicz A; Kalberer CP
    Cytotherapy; 2010 Oct; 12(6):750-63. PubMed ID: 20491532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
    Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human interferon-alpha increases the cytotoxic effect of CD56(+) cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines.
    Durrieu L; Gregoire-Gauthier J; Dieng MM; Fontaine F; le Deist F; Haddad E
    Cytotherapy; 2012 Nov; 14(10):1245-57. PubMed ID: 22974386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts.
    Linn YC; Lau LC; Hui KM
    Br J Haematol; 2002 Jan; 116(1):78-86. PubMed ID: 11841399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells.
    Bremm M; Pfeffermann LM; Cappel C; Katzki V; Erben S; Betz S; Quaiser A; Merker M; Bonig H; Schmidt M; Klingebiel T; Bader P; Huenecke S; Rettinger E
    Front Immunol; 2019; 10():1218. PubMed ID: 31214182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells.
    Lelaidier M; Dìaz-Rodriguez Y; Cordeau M; Cordeiro P; Haddad E; Herblot S; Duval M
    Oncotarget; 2015 Oct; 6(30):29440-55. PubMed ID: 26320191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
    Boeck CL; Amberger DC; Doraneh-Gard F; Sutanto W; Guenther T; Schmohl J; Schuster F; Salih H; Babor F; Borkhardt A; Schmetzer H
    J Immunother; 2017; 40(6):224-248. PubMed ID: 28557814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotype and Function of Activated Natural Killer Cells From Patients With Prostate Cancer: Patient-Dependent Responses to Priming and IL-2 Activation.
    Hood SP; Foulds GA; Imrie H; Reeder S; McArdle SEB; Khan M; Pockley AG
    Front Immunol; 2018; 9():3169. PubMed ID: 30761160
    [No Abstract]   [Full Text] [Related]  

  • 20. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation.
    Alvarnas JC; Linn YC; Hope EG; Negrin RS
    Biol Blood Marrow Transplant; 2001; 7(4):216-22. PubMed ID: 11349808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.